supply of neuraminidase inhibitors related to reduced influenza a (h1n1) mortality during the 2009–2010 h1n1 pandemic an ecological study供应相关的神经氨酸酶抑制剂降低甲型流感(h1n1)死亡率在2009 - 2010年甲型h1n1流感大流行的生态研究.pdfVIP

Supply of Neuraminidase Inhibitors Related to Reduced Influenza A (H1N1) Mortality during the 2009–2010 H1N1 Pandemic: An Ecological Study 1. 1. 1 1 1 Paula E. Miller , Aksharananda Rambachan , Roderick J. Hubbard , Jiabai Li , Alison E. Meyer , 2 3 4 3 Peter Stephens , Anthony W. Mounts , Melissa A. Rolfes *, Charles R. Penn 1 Department of Statistics, Saint Olaf College, Northfield, Minnesota, United States of America, 2 IMS Health, London, United Kingdom, 3 World Health Organization, Geneva, Switzerland, 4 Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America Abstract Background: The influenza A (H1N1) pandemic swept across the globe from April 2009 to August 2010 affecting millions. Many WHO Member States relied on antiviral drugs, specifically neuraminidase inhibitors (NAIs) oseltamivir and zanamivir, to treat influenza patients in critical condition. Such drugs have been found to be effective in reducing severity and duration of influenza illness, and likely reduced morbidity during the pandemic. However, it is less clear whether NAIs used during the pandemic reduced H1N1 mortality. Methods: Country-level data on supply of oseltamivir and zanamivir were used to predict H1N1 mortality (per 100,000 people) from July 2009 to August 2010 in forty-two WHO Member States. Poisson regression was used to model the association between NAI supply and H1N1 mortality, with adjustment for economic, demographic, and health-related confounders.